Please login to the form below
Pfizer/BioNTech
This page shows the latest Pfizer/BioNTech news and features for those working in and with pharma, biotech and healthcare.
Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
One vaccine is monovalent and the other is bivalent, made up from a combination of the Pfizer/BioNTech COVID-19 vaccine and a vaccine candidate designed to target the spike protein ... The Pfizer/BioNTech COVID-19 vaccine, which is based on BioNTech’s
Latest news
-
Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
The data shows that a booster dose of both Omicron-adapted vaccines gave a considerably higher immune response against Omicron BA.1, compared to Pfizer/BioNTech’s current COVID-19 vaccine. ... One vaccine is monovalent and the other is bivalent, made
-
FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants
Pfizer and BioNTech’s COVID-19 vaccine has been given emergency use authorisation by the US Food and Drug Administration (FDA) for children aged six months through to four years old. ... The three 3µg doses of the Pfizer/BioNTech COVID-19 vaccine
-
Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
Pfizer and BioNTech have announced recent data from a top-line safety, immunogenicity and vaccine efficacy phase 2/3 trial assessing a third 3µg dose – one-tenth of the adult dosage – ... It was found that this dosage of the Pfizer/BioNTech COVID-19
-
FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster
Pfizer/BioNTech have been given an expanded emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) for its COVID-19 vaccine. ... It is the same formulation and strength as previous Pfizer/BioNTech COVID-19 vaccine doses.
-
Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA
In a recent interview, Pfizer CEO Albert Bourla told CNBC that the company plans to submit an application of data to the US Food and Drug Administration (FDA) highlighting the need ... In January Pfizer/BioNTech began a study to evaluate the safety of an
More from news
Approximately 81 fully matching, plus 131 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
In the UK, the looming Brexit sparked new models of regulatory approval and fast-track opportunities, as recently observed in the rapid approval of Pfizer’s COVID-19 vaccine. ... So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University
-
Working together against COVID-19
Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same. ... A number of top pharma companies are included in the newly
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
What does the future hold for clinical trial recruitment?
This work is ongoing as the virus mutates; last month, it was announced that Pfizer and BioNTech had started clinical trials for a new Covid vaccine targeting the Omicron variant.
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
In the past year, we have seen partnerships between companies such as Pfizer and BioNTech; Oxford University and AstraZeneca and more recently GSK and CureVac. ... doi:10.1136/bmj.n129. 24. Dean G, Reuters. The UK approved Pfizer’s vaccine too quickly
-
What does the COVID-19 vaccine mean for the future of R&D?
Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
-
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
-
Mistrust in medical research: a patient perspective
Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
